World's First CAR-T Therapy for Solid Tumors Set to Launch in China
核心洞察
Satri-cel (CT041), the world's first CAR-T therapy specifically targeting solid tumors, is expected to become available in China in the first half of 2026.
Clinical studies demonstrated a 41% objective response rate in advanced gastric and gastroesophageal cancers, representing more than 10-fold improvement over conventional therapies.
The therapy targets Claudin18.2 (搜索), a biomarker commonly found in gastric and pancreatic cancers, addressing a major unmet medical need.
A groundbreaking CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients.
The therapy, known as satri-cel (CT041), represents the world's first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2 (搜索), a biomarker commonly found in gastric and pancreatic cancers.
Revolutionary Approach to Solid Tumor Treatment
CAR-T therapy is a highly personalized treatment that uses a patient's own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time.
While CAR-T has already transformed outcomes in blood cancers, this new therapy represents a major breakthrough in treating solid tumors, where effective options have historically been limited.
Promising Clinical Outcomes
Clinical studies conducted in China have demonstrated encouraging outcomes for patients with advanced gastric and gastroesophageal cancers. The results show an objective response rate (ORR) of approximately 41%, significantly higher than standard treatments, representing more than 10-fold improvement versus conventional therapies in some comparisons.
Additionally, progression-free survival was extended to approximately 4.7 months compared to 1.7 months with standard care. These results have been presented at leading international conferences and published in top-tier medical journals, highlighting the global significance of this therapy.
Addressing Critical Medical Need
Advanced gastric and pancreatic cancers remain among the most difficult cancers to treat, with limited effective options in later lines of therapy and poor survival outcomes. This CAR-T therapy offers a new treatment pathway for patients who have exhausted conventional options.
The therapy may be suitable for patients who have advanced or metastatic gastric or gastroesophageal cancer, have received at least two prior lines of treatment, show Claudin18.2 (搜索)-positive tumors, and meet clinical eligibility criteria. Each patient will undergo a detailed medical evaluation to determine suitability.
Future Implications
This therapy represents a milestone in oncology, opening the door for CAR-T treatments beyond blood cancers and into solid tumors. Ongoing research is exploring broader applications, including earlier-stage treatment and additional tumor types, potentially expanding the therapeutic landscape for cancer patients worldwide.